Climb Bio Welcomes Susan Altschuller as CFO to Enhance Leadership

Climb Bio Strengthens Leadership with New CFO

Climb Bio, Inc. (NASDAQ: CLYM), a clinical-stage biotechnology company focused on developing therapies for immune-mediated diseases, has announced the appointment of Susan Altschuller, Ph.D., MBA, as its new Chief Financial Officer. This strategic hire is set to enhance Climb Bio's leadership team and drive the company's financial strategies forward.

Bringing Extensive Experience to Climb Bio

Dr. Altschuller joins Climb Bio with over 20 years of rich experience in strategic and financial leadership within the biopharmaceutical sector. Her previous role as Chief Financial Officer at Cerevel Therapeutics involved navigating the company through its significant acquisition by AbbVie, a partnership valued at $8.7 billion. Additionally, her tenure at ImmunoGen was marked by support for the company's first commercial launch, highlighting her solid track record in financial execution and operational strategy.

A Proven Biopharmaceutical Leader

In her career, Dr. Altschuller has also held critical positions at Alexion, where she managed investor relations, along with enterprise finance roles at Bioverativ, which is known for its focus on hemophilia treatments. Starting her career as a consultant with the Frankel Group, she has built an impressive portfolio of leadership experiences that are sure to benefit Climb Bio and its mission.

Excitement for Future Developments

Commenting on her new position, Dr. Altschuller expressed enthusiasm for Climb Bio's vision. "I am inspired by the potential of Climb Bio's pipeline to make a significant impact on immune-mediated diseases," she stated. As the company advances its programs, which include budoprutug and CLYM116, her expertise will be pivotal in guiding the financial strategies that will empower Climb Bio as it reaches critical clinical milestones.

Advancing Clinical Pipelines

Climb Bio is currently focused on advancing budoprutug, an anti-CD19 monoclonal antibody that has demonstrated efficacy in depleting B-cells. This therapy has the potential to address various B-cell mediated diseases. Meanwhile, CLYM116 is an anti-APRIL monoclonal antibody being developed specifically for the treatment of IgA nephropathy, and the clinical development of these therapies aligns with Dr. Altschuller's leadership experience.

Equity Award for Dr. Altschuller

In connection with her appointment, Climb Bio has issued an inducement equity award to Dr. Altschuller. This award, established under the company's 2025 Inducement Plan, includes a non-statutory stock option to purchase 600,000 shares of Climb Bio common stock. The exercise price is set at the closing stock price as reported on her start date, reinforcing the company’s commitment to aligning her interests with those of its shareholders.

Commitment to Shareholder Value

Dr. Altschuller's stock option will vest over four years, ensuring her ongoing contribution to the company’s long-term success. She emphasized the importance of creating value for shareholders through the advancement of Climb Bio's promising therapeutic portfolio. This strategic focus on both innovation and fiscal responsibility sets the tone for the company’s trajectory in the biotechnology space.

About Climb Bio, Inc.

Climb Bio is dedicated to developing therapeutics that address severe immune-mediated diseases. Their innovative pipeline, featuring budoprutug and CLYM116, underscores a commitment to offering patients effective treatment options. As the company evolves, it remains focused on patient-centric solutions and scientific advancements in the field of immunology.

Contact and Further Information

For more details or inquiries, interested parties can contact Carlo Tanzi, Ph.D., at Kendall Investor Relations via email at catanzi@kendallir.com. Stay updated on Climb Bio's progress and initiatives as it continues to expand its role in the biopharmaceutical market.

Frequently Asked Questions

Who is the new Chief Financial Officer at Climb Bio?

Susan Altschuller, Ph.D., MBA, has been appointed as the new Chief Financial Officer at Climb Bio.

What experience does Dr. Altschuller bring to Climb Bio?

Dr. Altschuller has over 20 years of experience in financial leadership within the biopharmaceutical industry, including key roles at Cerevel Therapeutics and ImmunoGen.

What are Climb Bio's primary therapeutic focuses?

Climb Bio focuses on developing treatments for immune-mediated diseases, with pipelines that include budoprutug and CLYM116.

How will Dr. Altschuller impact Climb Bio?

Her extensive experience in strategic financial management is expected to significantly contribute to Climb Bio's clinical advancements and financial strategies.

What is the significance of the inducement equity award for Dr. Altschuller?

The inducement equity award aligns Dr. Altschuller’s incentives with the company's performance, ensuring her commitment to enhancing shareholder value.

About The Author

Hi there, As a writer and financial specialist, Henry Turner is passionate about guiding people through the complex world of finance. Having worked in finance for many years, I am an expert at simplifying difficult financial ideas into understandable, useful insights for my blog and articles. My goal is to arm you with the confidence and information you need to make wise financial choices.

Writing for a number of financial blogs has allowed me to interact with readers from novice investors looking for fresh ideas to seasoned investors starting their financial journeys. My mission is to enable everyone to understand and access finance, so enabling you to confidently and clearly reach your financial goals. I appreciate you traveling with me toward success and financial literacy.

Contact Henry Turner privately here. Or send an email with ATTN: Henry Turner as the subject to contact@investorshangout.com.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.